Brain gene therapy tested for Parkinson's – early results in

NCT ID NCT05603312

Completed Disease control Sponsor: MeiraGTx, LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tested a gene therapy for Parkinson's disease. The treatment involved delivering a gene called GAD into a brain region that controls movement. Only 14 people took part, and the main goal was to check safety, not whether it works. The study is now complete.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AAV-GAD (gene therapy)
What this could lead to: If successful, this could point toward a new way to control Parkinson's symptoms by delivering a gene that helps calm overactive brain signals.
What could go wrong: This was a very small, early-phase trial focused on safety, not effectiveness. The gene therapy requires brain surgery, which carries risks like infection or bleeding. It may not improve symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON'S DISEASE

Contacts and locations

Locations

Columbia University Irving Medical Center

New York, New York, 10032, United States
Henry Ford West Bloomfield Hospital

West Bloomfield, Michigan, 48322, United States
Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States
Weill Cornell Medicine

New York, New York, 10021, United States
West Virginia University

Morgantown, West Virginia, 26506, United States
Yale University - Yale New Haven Hospital

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.